secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001161697-22-000375
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q2 net sales up 18.4% to $6.5M; raises FY revenue guidance but lowers margin forecast
--------------------------------------------------------------------------------

- Net sales $6.5M (+18.4% YoY) driven by novel therapies (NRE milestone) and core growth; backorders $0.3M.
- GAAP net loss $2.9M (EPS -$0.07) vs $1.1M loss a year ago; adjusted EPS -$0.06.
- Raises FY 2022 revenue guidance to $27.0–27.5M (from $26.5–27.0M); lowers gross margin guidance to 55–60% (from 60%).
- Manufacturing transfer to contract manufacturer delayed to Q1 2023 (from Q4 2022); cash $18.3M at quarter end.
- Expanded novel therapies pipeline with two new biopharmaceutical agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/0001161697-22-000375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-22-000375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer